UBS Initiates Coverage of Solid Biosciences at Buy
Fintel reports that on October 15, 2026, UBS initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with a Buy recommendation.
Prior to this rating action, the stock closed at $5.46 on October 14, 2026. On October 15, 2026, the latest close was recorded at $5.74. Over a one-week period, the stock experienced a price change of -15.84% from a baseline close of $6.82 on October 8, 2026. Over a one-month period, the price change was -31.42% from a baseline close of $8.37 on September 15, 2026.
Separately from the individual rating by UBS, the broader consensus target data for the company shows a current consensus target mean of $19.30 and a median of $18.36 as of October 2, 2026. This current mean target represents an implied change of +236.26% from the stock's valuation. Previously, on September 15, 2026, the prior consensus target mean was $19.38, representing a consensus target revision of -0.40%.
In terms of aggregate analyst recommendations, the current recommendation period starting September 1, 2026, shows a total of 19 recommendations, consisting of 8 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell ratings. This results in a positive recommendation percentage of 94.7%, a hold percentage of 5.3%, and a negative percentage of 0.0%. These figures are identical to the prior recommendation period starting August 1, 2026, which also had 19 total recommendations with 8 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell ratings.
Solid Biosciences last reported earnings on August 6, 2026, posting an actual EPS of -0.38 compared to an estimated EPS of -0.4776. The actual revenue and estimated revenue for the quarter were both $0.00. The company's upcoming earnings date is scheduled for November 2, 2026. In other analyst activity, RBC Capital recently initiated coverage on September 16, 2026, with an Outperform rating.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 15, 2026 | UBS | Buy | initiated coverage | |
| September 16, 2026 | RBC Capital | Outperform | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.